Skip to main content

Table 5 Results of stem cell transplantation in MDS patients with MF = 0/1 or MF = 2/3 (n = 141)

From: Allogeneic stem cell transplantation may overcome the adverse impact of myelofibrosis on the prognosis of myelodysplastic syndrome

  MF = 0/1) (n = 121) MF = 2/3 (n = 20) P
Cumulative incidence of neutrophil reconstruction at day + 30 98.3% 95.0% 0.107
Cumulative incidence of platelet reconstruction at day + 30 87.6% 80.0% 0.303
Median days to neutrophil reconstruction(> 0.5 × 109/L) (range) 12(7–34) 14(10–45) 0.005
Median days to platelet reconstruction(> 20X109/L) (range) 14(8–68) 18(8–65) 0.045
Acute GVHD grade II–IV 45(37.2%) 6(30%) 0.535
Chronic GVHD 67(55.4%) 10(50%) 0.655
2 year cumulative incidence of relapse 12.0% 16.8% 0.910
2 year non-replase mortality 26.0% 21.7% 0.441